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Abstract
Background: Aberrant activation of Wnt/b-catenin signaling promotes the development of several cancers. It has been
demonstrated that the Wnt signaling pathway is activated in chronic lymphocytic leukemia (CLL) cells, and that
uncontrolled Wnt/b-catenin signaling may contribute to the defect in apoptosis that characterizes this malignancy. Thus,
the Wnt signaling pathway is an attractive candidate for developing targeted therapies for CLL.
Methodology/Principal Findings: The diuretic agent ethacrynic acid (EA) was identified as a Wnt inhibitor using a cell-
based Wnt reporter assay. In vitro assays further confirmed the inhibitory effect of EA on Wnt/b-catenin signaling. Cell
viability assays showed that EA selectively induced cell death in primary CLL cells. Exposure of CLL cells to EA decreased the
expression of Wnt/b-catenin target genes, including LEF-1, cyclin D1 and fibronectin. Immune co-precipitation experiments
demonstrated that EA could directly bind to LEF-1 protein and destabilize the LEF-1/b-catenin complex. N-acetyl-L-cysteine
(NAC), which can react with the a, b-unsaturated ketone in EA, but not other anti-oxidants, prevented the drug’s inhibition
of Wnt/b-catenin activation and its ability to induce apoptosis in CLL cells.
Conclusions/Significance: Our studies indicate that EA selectively suppresses CLL survival due to inhibition of Wnt/b-
catenin signaling. Antagonizing Wnt signaling in CLL with EA or related drugs may represent an effective treatment of this
disease.
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Introduction
Chronic lymphocytic leukemia (CLL) is one of the most
common hematological malignancies in the United State. Despite
significant advances in the treatment of CLL and its complications,
there is no cure for this disease. CLL is characterized by a
progressive accumulation of morphologically mature but func-
tionally incompetent lymphocytes in peripheral blood, secondary
lymphoid tissue, and bone marrow [1]. However, it remains
unclear how the clonal expansion of B-lymphocytes in CLL is
caused by an imbalance between signals that promote cell survival
and apoptosis [2,3,4]. The identification of molecular pathways
that the malignant cells use for survival in CLL may thus provide
novel potential targets for therapy.
Wnt signaling affects fundamental development pathways by
regulating cell proliferation and differentiation. Aberrant activa-
tion of the Wnt signaling pathway has major oncogenic effects
[5,6,7,8,9]. In the canonical Wnt pathway, the secreted Wnt
proteins bind to a receptor complex, consisting of a member of the
Frizzled (Fzd) family, and the low-density lipoprotein-receptor-
related proteins (LRP) 5 or LRP6. Subsequently the cytoplasmic
adaptor protein disheveled (Dvl) is phosphorylated and inhibits
glycogen synthase kinase (GSK)-3b activity through its association
with axin. Unphosphorylated b-catenin accumulates in the
cytoplasm and translocates into the nucleus, where it interacts
with T cell (TCF) and lymphoid-enhancing (LEF) factors to
activate transcription of Wnt target genes [5,6,8]. Recently, it has
been demonstrated that the Wnt signaling pathway is activated in
CLL cells, and that uncontrolled Wnt/b-catenin signaling may
contribute to the defect in apoptosis that characterizes this
malignancy [10,11]. In comparison to normal blood B cells,
LEF-1 is the most highly upregulated mRNA in CLL cells [12].
The orphan Wnt receptor ROR1, whose promoter contains
multiple LEF-1 regulatory motifs, is also highly expressed in CLL.
Thus, the Wnt signaling pathway, and especially LEF-1, are
attractive candidates for developing targeted therapies for CLL.
Ethacrynic acid (EA), a once commonly used loop diuretic drug,
was previously shown to be cytotoxic toward primary CLL cells
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cytotoxicity was attributed to the drug’s known capacity to inhibit
glutathione S-transferase (GST), causing increased cellular oxida-
tive stress. However, a recent study [17]showed that the
antioxidant N-acetyl-L-cysteine (NAC) protected cells from EA-
induced apoptosis with no effect on cellular glutathione (GSH)
levels, whereas the free radical scavenger 3-t-butyl-4-hydroxyani-
sole (BHA) did not, suggesting the existence of additional or
alternative pathways that are altered by the drug. In a previous
study, we prepared a series of EA analogs, and showed that their
cytotoxicity to CLL cells depended upon the a, b-unsaturated
ketone in the molecules, that can react with cellular thiols by
Michael addition [18].
Here we demonstrate that EA can directly interact with LEF-1
protein in CLL cells, and destabilize the LEF-1/b-catenin complex.
Importantly, EA exhibited selective cytotoxicity towards primary
CLL cells, possibly due to the dependence of the malignant
lymphocytes on proteins regulated by LEF-1 transcription.
Materials and Methods
Human Samples
Blood samples were collected by the Chronic Lymphocytic
Leukemia Research Consortium, after obtaining informed consent
from patients fulfilling diagnostic criteria for CLL, at all disease
stages. Institutional review board approval was obtained from
University of California San Diego (Approval#080918) for the
procurement of patient samples in this study, in accordance with
the Declaration of Helsinki. The patients in this study have given
written informed consent to publication of their case details.
Chemical Reagents
Ethacrynic acid (EA), N-acetyl-L-cysteine (NAC), pyrrolidine-
dithiocarbamate ammonium salt (PDTC), and 3-t-butyl-4-hydro-
xyanisole (BHA) were from Sigma-Aldrich (St. Louis, MO). A
Gen-plus collection of 960 known drugs was obtained from
Microsource (Gaylordsville, CT).
Transfection and Screening of Drug Library
The human embryonic kidney cell line HEK293 (American
Type Culture Collection, Rockville, MD) was transfected using the
FuGene transfection reagent (Roche Diagnostics GmbH, Man-
nheim, Germany) according to the manufacturer’s instruction.
The reporter plasmids TOPflash and FOPflash were gifts from
H. Clevers (University of Utrecht, Utrecht, The Netherlands). The
pNFAT-Luc reporter was purchased from BD Biosciences. The
expression plasmids encoding Wnt1, Wnt3, LRP6, Dvl, b-catenin
and NFATc have been described previously [10,19].
For screening of the drug library, HEK293 cells were grown for
at least 24 h in 10 cm plates prior to transfection. At ,50%
confluence, cells were transfected with 5 mg of TOPflash reporter,
1 mg expression vector for Dvl, 1 mg of control plasmid
pCMXbgal and carrier DNA pcDNA3 plasmid for a total
of10 mg/plate. After transfection for 24 h, cells were harvested
and dispersed in 96-well microtiter plates. Then the cells were
treated with the different agents, generally at 10 mM and 50 mM
for the initial screen. After overnight incubation, the cells were
lysed in 1x potassium phosphate buffer, pH 7.8, containing 1%
Triton X-100, and luciferase activities were assayed in the
presence of substrate using a microtiter plate luminometer
(MicroBeta TriLux, Gaithersburg, MD). The luciferase values
were normalized for variations in transfection efficiency using the
b-galactosidase internal control. EA, and other compounds that
were scored positive, had $30% inhibition of TOPflash activity
when compared to the designated control cultures. In other
experiments, transient transfections were performed in 12-well
plates. HEK293 or SW480 cells were transfected with 0.5 mgo f
reporter plasmid, 0.1 mg of control plasmid pCMXbgal, 0.1–
0.2 mg expression plasmids, and carrier DNA pcDNA3 plasmid for
a total of 1 mg/well. After 16 h, the cells were washed and treated
with 50 mM EA or solvent (DMSO) for 24 h. Then luciferase
values were determined. In the Results section, data are expressed
as fold stimulation of luciferase activity compared to the basal
level. All the transfection results represent means of a minimum of
three independent transfections assayed in duplicate, 6the
standard error of the mean (SEM).
Activation of TOPflash Reporter Using Wnt3a
The Super8XTOPflash construct (kindly provided by Dr. R.
Moon) was stably transfected into HEK293 cells, and single cell
clones were isolated. The stable Super8XTOPflash reporter cell
line displays low basal luciferase activity and strong luciferase
induction in response to Wnt3a stimulation. Preparation of Wnt3a
and Wnt3a stimulations were performed as described [20,21].
Cell Viability Assay with 3-[4,5-Dimethylthiazol-2-yl]-2,5-
diphenyl Tetrazolium Bromide (MTT)
Primary CLL cells were collected from patients’ peripheral
bloods after informed consent, and isolated by Ficoll/Hypaque
density-gradient centrifugation as previously described [10].
Normal peripheral blood mononuclear cells were also purified as
described [10]. The cells were resuspended in RPMI 1640
medium with 10% fetal bovine serum (Gemini Bio-Products,
West Sacramento, CA), and antibiotics at 37uC, 5% CO2. Cell
viability after drug exposure was assessed by MTT assay. Fresh
CLL or peripheral blood mononuclear cells were plated at
2.5610
5 per well in 96-well plates. After 48 h, 1/10 volume of
5 mg/ml MTT was added, and cells were incubated at 37uC
overnight. Finally, K volume of Lysis buffer was added to the
cultures, and ODs at 570 nm were read and recorded.
Cell Apoptosis Assays
The apoptosis of the CLL cells was determined by the analysis
of mitochondrial transmembrane potential (DYm) using 3, 39-
dihexyloxacarbocyanine iodine (DiOC6) and by cell membrane
permeability to propidium iodide (PI). Primary CLL cells were
treated with 3 mM EA, 1 mM NAC, 100 mM BHA or combined
treatment as indicated. After treatment for 48 h, the cells were
stained with DiOC6 and PI and analyzed by flow cytometry. For
each assay, 100 ml of the cell culture at a density of 10
6 cells/ml
was collected at the indicated time points and transferred to
polypropylene tubes containing 100 ml of 60 nM DiOC6 and
10 mg/ml PI in FACS buffer containing serum deficient RPMI
medium with 0.5% bovine serum albumin (BSA). The cells were
then incubated at 37uC for 15 minutes and analyzed within 30
minutes by flow cytometry using a FACSCalibur (Becton
Dickinson). Fluorescence was recorded at 525 nm (FL-1) for
DiOC6 and at 600 nm (FL-3) for PI. The apoptotic cells were
determined by calculating the percentages of the DiOC6
+/PI
2
CLL populations.
RNA Isolation and Real-Time PCR
PrimaryCLL cellsfrom three patients weretreated with increasing
amounts of EA for 16 h. Total RNA was isolated from 1610
6 CLL
cells by Trizol reagent (Invitrogen, Carlsbad, CA). The RNAsamples
were further purified using a Qiagen RNeasy Protect kit (Qiagen,
Valencia, CA). The mRNA levels were quantified in duplicate by real
EA Inhibits Wnt Signaling
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Rad Laboratories, Hercules, CA) using the following primer sets:
cyclin D1 forward 59GGCGGAGGAGAACAAACAGA39, reverse
59 TGGCACAAGAGGCAACGA 39 and probe 59TCCGCAAA-
CACGCGCAGACC 39, Fibronectin forward 59ACCTACGGAT-
GACTCGTGCTTT39, reverse 59TTCAGACATTCGTTCC-
CACTCA39 and probe 59CCTACACAGTTTCCCATTAT-
GCCGTTGGA 39, Fzd5 forward 59 CGCGAGCACAACCA-
CATC39, reverse 59 AGAAGTAGACCAGGAGGAAGACGAT39
and probe 59 TACGAGACCACGGGCCCTGCAC39.L E F - 1
mRNA level was detected using TaqMan Gene Expression assay
Hs00212390_m1 (LEF-1) (Applied Biosystems). PCR was performed
using Taqman PCR CoreReagents (Applied Biosystems, Foster City,
CA, USA) according to the manufacturer’s instructions. PCR cycles
consisted of an initial denaturization step at 95uCf o r1 5sa n da t
60uC for 60 s. PCR amplification of 18S RNA was done for each
sample as a control for sampleloading and to allow for normalization
between samples. The data were analyzed using the comparative Ct
method, where Ct is the cycle number at which fluorescence first
exceeds the threshold. The DCt values from each cell line were
obtained by subtracting the values for 18S Ct from the sample Ct.
OnedifferenceofCtvaluerepresentsa2-folddifferenceinthelevelof
mRNA. The mRNA level was expressed as percentage with respect
to control (100%).
Preparation of Ethacrynic Acid Antiserum
A conjugate of EA with Keyhole Limpet Hemocyanin (KLH,
Sigma) was prepared by thiolation of KLH with N-succinimidyl S-
acetylthioacetate (SATA), followed by allowing the SATA-KLH
conjugate to form a Michael adduct with EA, as described [22].
Immunization ofrabbitswasperformed bythree 1 mlsubcutaneous
injections of approximately 0.4 mg EA-KLH conjugates. Complete
Freund’s adjuvant was used for the first injection. The second and
third injections were performed 3 and 6 weeks after the first, using
incomplete adjuvant. The rabbits were bled six weeks after the third
injection for preparation of antiserum. The specificity of the
antibody was confirmed by both ELISA and immunoblotting using
EA conjugated to a different antigen (ovalbumin).
Co-Immunoprecipitation and Immunoblotting
Primary CLL cells and SW480 cells were treated with the
indicated amounts of EA as described in the Figure legend. Cells
were washed twice with PBS and resuspended in 0.5 ml lysis buffer
(20 mM Tris-HCl, pH 8.0/10% glycerol/5 mM MgCl2/0.15 M
KCl/0.1% Nonidet P-40 with protease inhibitors). For CLL cells,
lysates of 1 to 2610
7 cells were incubated with anti-LEF-1
antibody at a 1:1000 dilution overnight at 4uC, and then with
saturating amounts of protein G plus/protein A agarose beads
(Calbiochem) at 4uC for 2 h before centrifugation at 15,000 g for
5 min. For SW480 cells, lysates of 0.5 to 1610
7 cells were
incubated overnight at 4uC with saturating amounts of agarose
beads linked to monoclonal antibodies specific for b-catenin (Santa
Cruz Biotechnology). The beads were washed twice with lysis
buffer and once with PBS. Bound proteins were eluted by boiling
the samples in SDS sample buffer and resolved by SDS/PAGE
followed by immunoblotting with anti-EA antibody (1:1000), anti-
LEF-1 antibody (1:1000) (BD Biosciences), anti-b-catenin antibody
(1:2000) (Santa Cruz Biotechnology), anti-a-catenin antibody
(1:2000) (GenWay). Horseradish peroxidase-conjugated anti-IgG
was used as the secondary antibody. The membranes were
developed using a chemiluminescence system (ECL detection
reagent, Amersham Pharmacia Life Science). For some experi-
ments, the immunoblots were imaged with an Odyssey Infrared
Imaging System (LI-COR Biosciences, Lincoln, NE). The
membranes were stripped with Re-Blot Western blot recycling
kit (Chemicon International, Temecula, CA) and reprobed.
Results
Inhibition of Wnt/b-Catenin Signaling by EA
To identify novel antagonists of Wnt/b-catenin signaling, we used
a 96-well plate-based TOPflash reporter system to screen the Gen-
plus drug library (Microsource) that contains 960 FDA-approved
drugs. In this system, transfected Dvl (an upstream activator of the
Wnt/b-catenin pathway) stimulated TCF/LEF response elements in
the TOPflash reporter gene. In accord with our earlier research, the
screen identified several non-steroidal anti-inflammatory drugs
(NSAIDs), PPARc,a n dR X R a l i g a n d sa sW n ta n t a g o n i s t s[ 1 9 ] .
However, no other compound classes inhibited reporter gene activity,
including many known cytotoxic agents. Surprisingly, the screen
identified ethacrynic acid (EA), but not other diuretic agents, as a
Wnt/b-catenin inhibitor. To further determine the inhibitory effect
of EA on Wnt signaling, the stable SuperTOPflash reporter cell line
was treated with Wnt3a and increasing concentrations of EA. Wnt3a
induced transcriptional activity of the SuperTOPflash reporter 300-
fold above the basal levels. EA blocked Wnt3a-induced transcription
in a dose-dependent manner (Figure 1A).
To explore possible targets of EA in the Wnt/b-catenin
pathway, the TOPflash reporter was activated by Wnt1/LRP6
or Wnt3/LRP6, Dvl and b-catenin, respectively, in transient
transfection assays. Treatment with EA reduced Wnt1/LRP6 or
Wnt3/LRP6, Dvl, and b-catenin-induced transcription in
HEK293 cells (Figure 1B). This action was specific, since the
drug had no effect on the FOPflash reporter (Figure 1C). In
addition, EA did not block NFATc-mediated transcription from a
NFAT reporter (Figure 1D). These results suggest that EA may
specifically inhibit Wnt/b-catenin signaling through targeting
either b-catenin itself or its downstream factors.
Selective Cytotoxicity of EA to Chronic Lymphocytic
Leukemia (CLL) Cells
We next tested the cytotoxicity of EA in different tumor cell
lines, and in primary CLL cells that are known to have constitutive
Wnt activation and very high levels of LEF-1. As shown in Table 1,
the mean 50% inhibitory concentration (IC50) of EA in these cell
lines was in the 40–200 mM range. However, primary CLL cells
are highly sensitive to EA. This drug showed selective cytotoxicity
with a mean IC50 of 8.56+/23 mM in primary CLL cells,
compared to 34.79+/215.97 mM in normal peripheral blood
mononuclear cells (P,0.001) (Table 1 & Figure 2). In addition, we
noted that obvious cell death occurred after treatment with EA for
48 hours (data not shown). These findings are in agreement with a
previous report by Twentyman et al [14].
EA Depresses the Expression of LEF-1, Cyclin D1 and
Fibronectin
To assess the inhibitory effects of EA on Wnt/b-catenin
signaling in CLL cells, real-time PCR was employed to detect
the expression of some Wnt target genes. LEF-1, cyclin D1 and
fibronectin are established target genes of the Wnt/b-catenin
pathway [23,24,25,26,27]. The expression of Fzd5 was also
detected in our experiments. Fzd5 is not a target gene of Wnt/
b-catenin signaling. To determine the ability of EA to alter LEF-1,
cyclin D1, fibronectin and Fzd5 transcript expression, CLL cells
from three patients were treated with the drug for 16 h, and then
analyzed by real-time PCR. Total RNA input was normalized to
the concentration of 18S RNA. As shown in Figure 3, EA
decreased LEF-1, cyclin D1 and fibronectin mRNA expression in
EA Inhibits Wnt Signaling
PLoS ONE | www.plosone.org 3 December 2009 | Volume 4 | Issue 12 | e8294Figure 1. Inhibition of Wnt/b-catenin signaling by EA. (A) HEK293 cells carrying a Wnt responsive reporter (Super 8XTOPflash) were treated
with Wnt3a (10 nM) and increasing concentrations of EA (20, 25, 30, 35 mM) for 18 hours. Cells were lysed and luciferase activity was quantified. Total
protein levels were determined by Bradford Assay and serve as a control for total cell number. (B) HEK293 cells were co-transfected with TOPflash
reporter construct, along with expression plasmids for Wnt1, Wnt3, LRP6, Dvl and b-catenin as indicated. After transfection for 24 h, the cells were
treated with 50 mM EA for another 24 hours, and then luciferase activities were determined. (C) HEK293 cells were transfected with FOPflash reporter
with or without an expression plasmid for b-catenin. After transfection, the cells were treated with 50 mM EA for another 24 hours. (D) HEK293 cells
were transfected with NFAT reporter and expression plasmid for NFATc. The cells were treated with 50 mM EA for 24 h, and then harvested, and
extracted for determination of luciferase activities. The results are expressed as fold induction of luciferase activity compared to the basal level, and
are the means of three experiments 6 SEM.
doi:10.1371/journal.pone.0008294.g001
EA Inhibits Wnt Signaling
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showed dose-dependent enhancement of Fzd5 expression
(Figure 3). It is unclear how EA enhances the expression of Fzd5.
EA Directly Interacts with LEF-1 and Destabilizes the LEF-
1/b-Catenin Complex
Since the initial results indicated that EA may target either b-
catenin itself or its downstream factors, we next explored whether
the drug could directly interact with any component of the b-catenin
complex. The unsaturated ketone in EA can undergo Michael
addition with free thiols. To detect such covalent modifications, we
prepared antibody to EA conjugated to an irrelevant protein carrier,
and used the antibody to probe CLL cells exposed to the drug by
immunoblotting. As expected, EA could interact with multiple
proteins in CLL extracts, but did not bind detectably to b-catenin
itself (data not shown). However, the antibody to EA consistently
recognized a 47 kD protein consistent with the approximate size of
LEF-1 (data not shown). To determine whether EA could indeed
directly interact with LEF-1, CLL cells that had been treated with
the drug were lysed, immunoprecipitated with anti-LEF-1 antibody,
and probed in immunoblots using the anti-EA antibody (Figure 4A).
The immunoprecipitated LEF-1 protein from CLL lysates treated
with EA at 10 mM for 8 h and 24 h reacted strongly with the anti-
EA antibody.
To test whether EA could similarly interact with LEF-1 in other
tumor cells, a human colon cancer cell line SW480 was tested. It
has been demonstrated that LEF-1 is constitutively associated with
b-catenin in SW480 cells [28]. If EA inhibits Wnt/b-catenin
signaling through directly interacting with LEF-1, one would
expect that the drug should bind to LEF-1 in the LEF-1/b-catenin
complex. Hence, an anti-b-catenin antibody was used to pull
down the b-catenin complex in a co-immunoprecipitation
experiment. SW480 cells were treated with the indicated amounts
of EA in Figure 4 for 16 hours. Cell lysates were immunoprecip-
itated with anti-b-catenin antibody. The precipitated b–catenin
could not be detected by anti-EA antibody (Figure 4B). However,
the anti-b-catenin antibody pulled down LEF-1 protein and EA
(Figure 4C), indicating that the drug may directly bind to LEF-1 in
the LEF-1/b-catenin complex in SW480 cells.
To determine the consequences of EA modification of the
LEF-1/b-catenin complex, SW480 cells were treated with
increasing concentrations of the drug, and after 16 hours, the b-
catenin complex was pulled down using antibody against b-
catenin. Immunoblot analysis demonstrated that EA decreased
LEF-1 levels in the b-catenin complex in a concentration-
dependent manner (Figure 5A). However, EA had little effect
on a-catenin levels. This result suggests that EA binding to
LEF-1 may lead to destabilization of the LEF-1/b-catenin
complex. In whole cell lysate, we observed that EA treatment
decreased the level of a-catenin. It is possible that EA may
downregulate the expression of a-catenin via some as yet
unknown mechanism.
We next checked EA effect on TOPflash activity in SW480
cells. EA exhibited dose-dependent inhibition at concentrations
Table 1. Cytotoxicity of EA in different tumor cell lines and
primary CLL cells.
Cell line name IC50-EA (mM)
*
Primary CLL cells 8.5663.0
Normal PBMC 34.79615.97
LNCap 46
PC3 67
HCT116 58
SW480 68
HT29 56
MCF-7 63
SK-Mel-28 122
HepG2 223
A549 178
U266 90
B16 201
RAMOS 174
*IC50 is the mean concentration of drug that reduced cell survival by 50% in at
least two experiments. Primary CLL cells were isolated from nine patients.
Peripheral blood mononuclear cells (PBMC) were isolated from five normal
individuals.
doi:10.1371/journal.pone.0008294.t001
Figure 2. Selective cytotoxicity of EA to CLL cells. Primary CLL cells or normal peripheral blood mononuclear cells (PBMC) were treated with
increasing concentrations of EA for 48 h. The cell viability was measured by MTT assay. The control condition was a 2-day incubation of the cells in
the medium alone, and the viability expressed as the percentage with respect to this control.
doi:10.1371/journal.pone.0008294.g002
EA Inhibits Wnt Signaling
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LEF-1/b-catenin complex (Figure 5B). This result suggests that
EA may inhibit LEF-1-mediated transcription through destabili-
zation of the LEF-1/b-catenin complex in colorectal cancer cells.
N-Acetyl-L-Cysteine (NAC) Prevents EA-Mediated Effects
on the Wnt/b-Catenin Pathway and on CLL Survival
Although previous reports showed cytotoxicity of EA in different
tumor cell lines, the mechanism of cell killing was unknown [14,17].
To examine if the inhibition of Wnt/b-catenin signaling by EA is
mediated by modulation of thiols, or by increased oxidative stress as
a result of GST inhibition, cells that had been co-transfected with
the TOPflash reporter and the Dvl expression plasmids were treated
with EA and various antioxidants (NAC, BHA and PDTC). NAC,
an antioxidant containing a reactivef r e et h i o lg r o u p ,s i g n i f i c a n t l y
prevented EA-induced inhibition of Wnt/b-catenin signaling. In
contrast, neither BHA, which scavenges reactive oxygen species
(ROS), but does not have a free thiol, nor PDTC, which does react
efficiently with EA, did not reverse the Wnt inhibition (Figure 6A).
Consistent with this result, neither a glutathione synthesis inhibitor
(buthionine sulfoximine, BSO) nor a superoxide dismutase inhibitor
(2-methoxyestradiol), blocked Wnt/b-catenin signaling in the cell-
based system (data not shown).
To test whether NAC has the ability to protect CLL cells from
EA-induced apoptosis, a highly EA-sensitive CLL sample was
treated with EA alone or combined with NAC for 48 hours. The
result showed that NAC (1 mM) significantly protected CLL cells
from EA-induced apoptosis, but the free radical scavenger BHA
(100 mM) had no effect (Figure 6B), suggesting that the inhibition
of Wnt/b-catenin signaling and apoptosis in CLL by EA is not
mediated by the generation of oxygen radicals.
Discussion
The Wnt signaling pathway has been shown to play a critical
role in the early phases of B lymphocyte development, but is
thought to be less important for the survival of normal mature B
cells [29]. Although CLL cells have the morphological character-
istics of mature B lymphocytes, they frequently over-express Wnt
pathway genes associated with pro-B or pre-B cells, including
Wnt3, Wnt16, the orphan Wnt receptor ROR1, and the LEF-1
transcription factor [10,11,12,30,31]. The immature pro-B cells
from LEF-1 deficient mice display increased sensitivity to
apoptosis [29], although the exact mechanism is unclear. We
hypothesized that interference with the Wnt/b-catenin/LEF-1
pathway might sensitize CLL cells to apoptosis. The results of the
present experiments support this supposition.
To identify potential pharmacologic antagonists of Wnt
signaling, a 960-member library of known drugs was screened
using a cell-based TOPflash reporter gene assay. Among the few
drugs that blocked the Wnt reporter gene activity, at
concentrations that did not affect a control reporter gene, was
the loop diuretic ethacrynic acid (EA). The antagonism was not
attributable to non-specific toxicity of EA. Moreover, neither
DNA damaging agents nor anti-metabolites used in cancer
therapy displayed inhibitory effects in this Wnt dependent
system. Experiments with the cell-based reporter system
demonstrated that EA inhibited Wnt/b-catenin signaling
mediated not only by Wnt3a, but also by Wnt/LRP6, Dvl
and b-catenin, respectively, suggesting that the drug may target
either b-catenin itself or its downstream factors. Subsequent
studies showed that EA could not bind to b-catenin. Instead, EA
directly interacted with LEF-1, and induced the destabilization
Figure 3. Effect of EA on LEF-1, cyclin D1, fibronectin and Fzd5 expression in CLL cells. CLL cells from three patients were treated with
increasing amounts of EA for 16 h. The mRNA levels of LEF-1, cyclin D1, fibronectin and Fzd5 were compared by real-time PCR. Total RNA input was
normalized based on the concentration of 18S RNA.
doi:10.1371/journal.pone.0008294.g003
EA Inhibits Wnt Signaling
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have free thiol groups that are required for maintenance of its
structure [32]. In cells whose survival depends upon LEF-1
activity, modification of these thiols by EA may be lethal.
Experiments with real-time PCR demonstrated that treatment
with EA caused a dose-dependent decline in the expression of three
Wnt target genes, LEF-1, cyclin D1 and fibronectin, which reflects
EA inhibition of Wnt/b-catenin signaling in CLLcells. However, EA
enhanced the expression of Fzd5 in a concentration-dependent
manner. Fzd5 is a member of Frizzled receptor family. It has been
shown to activate both canonical and noncanonical Wnt pathways
through binding Wnt proteins such as Wnt5a, Wnt7a and Wnt11
[33,34,35]. Interestingly, a recent study demonstrated that apoptotic
agents imatinib and etoposide could alsoup-regulate Fzd5 expression
in the myeloid cell lines K562 and HL60 [36]. We speculate that the
increased expression of Fzd5 might correlate with an apoptotic
process. Further studies are needed to confirm our speculation.
EA is a loop diuretic drug that was formerly widely used, and
demonstrated an excellent safety profile, despite its a, b-unsaturated
ketone, that can modify free thiol residues of proteins. Our previous
studies demonstrated that reduction of the C-C double bond in EA
abrogated its ability both to block Wnt signaling and to impair CLL
survival [18]. Here we showed that N-acetyl-L-cysteine (NAC)
significantly prevented the EA-mediated inhibition of the Wnt/b-
catenin pathway and EA-induced apoptosis in CLL cells. NAC is a
known precursor and upregulator of GSH. It may mediate its
functions by formation of GSH-conjugates that can be removed by
the multidrug resistance pump or by directly reversing EA-alkylated
cysteine residues. To determine whether depletion of GSH is
associated with the inhibition of Wnt/b-catenin signaling, buthio-
ninesulfoximine(BSO)wasusedtodepleteGSHincells.Treatment
withBSO did not inhibit Wnt/b-catenin signaling (data not shown),
suggesting that the depletion of GSH is probably not responsible for
EA effect on Wnt/b-catenin signaling. Since EA is able to increase
cellular oxidative stress through inhibiting GST, we also tested the
effect of two free radical scavengers, BHA and PDTC, on EA-
mediated inhibition of Wnt/b-catenin signaling. Both scavengers
could not prevent EA-induced inhibition (Figure 6A). Moreover, we
didnot observe any significantincreaseinthe levelsofO2
2orH2O2
in CLL cells treated with EA (results not shown). These results
indicate that increased oxidative stress is not responsible for the
selective killing of CLL cells by EA.Similarly, Aizawa et al. reported
that EA could induce cell death in a human colon cancer cell line
(DLD-1) via an oxidative stress independent mechanism [17].
Our experiments demonstrated potent cytoxicity of EA in primary
CLL cells with IC50 of 8.56+/23 mM, while the IC50 for EA
inhibition of Wnt3A-induced transcription in HEK293 is about
25 mM, and the EA concentration required to destabilize the LEF-1/
b-catenin complex is at least 60 mM. This difference reflects the cell
type specific effect on EA sensitivity. CLL cells are known to have low
levels of GSH that can react with EA [37]. There is also differential
dependence of cell survival on LEF-1/b-catenin signaling, which is
probably critical for CLL, but not many other cell types.
Compared to cultured tumor cell lines and to normal peripheral
blood mononuclear cells, primary CLL cells were 5–50 fold more
sensitive to the cytotoxic effects of EA. It is tempting to speculate
that the sensitivity may be related to the high levels in CLL of
LEF-1 and its downstream effectors such as ROR1, compared to
most other cell types [12,31]. Accordingly, LEF-1 could be a
critical target for chemotherapy in CLL cells.
Figure 4. EA binds to LEF-1 in primary CLL and SW480 cells. (A) lysates from CLL cells exposed to 10 mM EA for 8 h or 24 h were
immunoprecipitated with anti-LEF-1 antibody. The immune complexes were analyzed by immunoblotting with anti-LEF-1 and anti-EA antibodies. (B)
SW480 cells were treated with indicated amounts of EA for 16 h. Cell lysates were immunoprecipitated with anti-b-catenin antibody (Santa Cruz
Biotechnology, Santa Cruz, CA). The immune complexes were analyzed by immunoblotting with anti-EA and anti-b-catenin antibodies. (C) SW480
cells were exposed to 50 mM of EA for 16 h and cell lysates were immunoprecipitated with anti-b-catenin antibody. The proteins in the
immunoprecipitates were resolved by SDS-PAGE, transferred, and probed with indicated antibodies. The LEF-1 protein band, as confirmed by
reactivity with LEF-1 specific antibody, stained positive with the anti-EA antibody only in the drug treated samples.
doi:10.1371/journal.pone.0008294.g004
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constitutively activated in CLL cells, and may render them
resistant to normal mechanisms of apoptosis [38,39]. Previous
studies have revealed that inhibition of NF-kB by drugs induces
apoptosis of CLL cells [39,40]. Han et al. reported that EA could
inhibit activation of the NF-kB pathway at multiple steps [41].
Thus, inhibition of NF-kB may synergize with Wnt antagonism to
impair CLL survival.
In addition, other signaling pathways may also contribute to the
cytotoxic effects of EA on various cell types. It has been reported
that the mitogen activated protein kinase (MAPK) pathway may be
involved in EA-induced cell death [17], but MAPK inhibitors are
not generally cytotoxic to CLL cells. A recent study showed that EA
and its butyl ester prodrug induced apoptosis in leukemia cells
through a hydrogen peroxide–mediated pathway, although in CLL
cells ant-oxidants other than N-acetyl-L-cysteine did not abrogate
either the drug’s toxicity or its ability to block Wnt signaling [42].
Because EA can bind to any free thiol, it is likely that the mechanism
of EA-induced cell death is variable and will depend upon cell type
and context. The high sensitivity of CLL cells to EA may be
attributed to its multiple effects on both Wnt and NF-kB signaling.
Recently, we could show a significant induction of apoptosis by
EA and ciclopiroxolamine (cic) in lymphoma and myeloma cells
[43]. Our data suggest that EA and cic can inhibit Wnt/b-catenin
signalling in lymphoma and myeloma cell lines. Our results are in
accordance with a recent report [44] that the canonical Wnt
signalling pathway is activated in multiple myeloma through
constitutively active b-catenin.
In summary, these experiments suggest that EA selectively
suppresses CLL survival in part due to inhibition of Wnt/b-
catenin signaling. Antagonizing Wnt signaling in CLL with EA or
related drugs may represent an effective treatment of this disease.
O’Dwyer and colleagues reported a phase I trial of EA in patients
with advanced solid tumors [45,46]. The toxicities associated with
the diuretic effect were easily managed with proper monitoring.
The maximum plasma concentrations of EA ranged from 2.66 to
9.38 mg/ml (8.8–30.9 mM) after i.v. administration. Moreover,
their results suggested that continuous i.v. infusion can be used to
achieve and sustain plasma concentrations greater than 1 mg/ml
(3.3 mM) for up to 3 hr [45]. In this study, we demonstrated the
selective cytotoxicity of EA in primary CLL cells with a mean IC50
of 8.56+/23 mM, which can be achieved in patients. In addition,
our preliminary results have shown that treatment with 3 mME A
enhanced fludarabine-mediated apoptosis of CLL cells (data not
shown). These results suggest that EA, by inhibition of the Wnt/b-
catenin pathway, compromised an important survival signal in
CLL cells and increased their vulnerability to cell killing induced
by chemotherapeutic agents. Therefore, there is a need to evaluate
the therapeutic potential of EA alone or combined with other
cytotoxic agents, such as fludarabine, in CLL patients.
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Figure 5. EA destabilizes the LEF-1/b-catenin complex. (A) SW480 cellsweretreatedwithincreasingamountsofEAfor16 h.Cellswere lysed,and
IP was completed with anti-b-catenin monoclonal antibody. The immune complexes were analyzed by immunoblotting with anti-LEF-1, anti-a-catenin
and anti-b-catenin antibodies. (B) EA inhibits Wnt/b-catenin signaling in SW480 cells. SW480 cells were transfected with TOPflash reporter and control
plasmid pCMXbgal. After transfection for 24 h, cells were treated with increasing concentrations of EA for another 24 h as indicated. Cells were then
harvested and luciferase values were determined. The results are expressed as relative luciferase activity (%) normalized to a b–galactosidase control.
doi:10.1371/journal.pone.0008294.g005
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